Understanding Type 2 Inflammation: Atopic Dermatitis

Track 1 - Understanding T2 Inflammation: Spotlight on Atopic Dermatitis
Track 2 - Understanding T2 Inflammation: Best Practices in Atopic Dermatitis Management

Learn About:

1. Payer care management initiatives and other opportunities to improve treatment access and overall quality of care
2. How T2 inflammation plays a central role in atopic dermatitis pathophysiology
3. The safety and efficacy of evolving treatments

Expert Faculty Presenters:

Dana McCormick, RPh, FAMCP Senior Director, Pharmacy Advisory Services Optum Insights Click here for biography Shawn G. Kwatra, MD Chair, Department of Dermatology and Chief of Service of Dermatology University of Maryland Medical Center (UMMC) Click here for biography Drake Reiter, PharmD Director, Pharmacy Operations Priority Health Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
Despite significant advances in understanding of the underlying etiology of AD, there remains a need to improve the overall management of AD to gain better control of the disease and reduce its clinical and humanistic burden. New systemic therapies that specifically target cytokines reveal the importance of major T2 cytokines IL-4 and IL-13 in AD pathophysiology. However, managed care professionals lack knowledge of how T2 inflammation impacts AD and the appropriate treatments to manage these patients. In addition, managed care professionals lack competence to effectively employ care management strategies based on current evidence that can improve treatment access and overall quality of care for patients with AD.

Educational Objectives
After completing this activity, the participant should be better able to:

• Describe how T2 inflammation plays a central role in atopic dermatitis pathophysiology
• Summarize safety and efficacy of treatments for patients with atopic dermatitis
• Assess payer care management initiatives and other opportunities to improve treatment access and overall quality of care based on current evidence from clinical trials and treatment guidelines

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™ per track. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Track 1: Spotlight on Atopic Dermatitis - 1.0 AMA PRA Category 1 Credit™
Track 2: Best Practices in Atopic Dermatitis Management – 1.0 AMA PRA Category 1 Credit™

Continuing Pharmacy Education
PACE designates this continuing education activity for 1.0 contact hour (0.10 CEUs) per track of the Accreditation Council for Pharmacy Education.

Track 1: Spotlight on Atopic Dermatitis - 1.0 contact hour
UAN: JA4008073-9999-24-283-L01-P
Type of Activity: Application

Track 2: Best Practices in Atopic Dermatitis Management - 1.0 contact hour
UAN: JA4008073-9999-24-284-L01-P
Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour per track.

Track 1: Spotlight on Atopic Dermatitis – 1.0 contact hour
Track 2: Best Practices in Atopic Dermatitis Management – 1.0 contact hour

Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

The PACE planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.